E
Edward Cole
Researcher at University Health Network
Publications - 20
Citations - 1119
Edward Cole is an academic researcher from University Health Network. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 12, co-authored 20 publications receiving 1006 citations. Previous affiliations of Edward Cole include University of Toronto.
Papers
More filters
Journal ArticleDOI
Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study
Hallvard Holdaas,Bengt Fellström,Edward Cole,Gudrun Nyberg,Anders G. Olsson,Terje R. Pedersen,Søren Madsen,Carola Grönhagen-Riska,Hans-Hellmut Neumayer,Bart Maes,Patrice M. Ambühl,Anders Hartmann,Beatrix Staffler,Alan G. Jardine +13 more
TL;DR: Fluvastatin produces a safe and effective reduction in LDL‐cholesterol associated with reduced risk of MACE in RTR, and the lipid‐lowering and cardiovascular benefits of fluvastatin are comparable to those of statins in other patient groups, and support use of fluVastatin in R TR.
Journal ArticleDOI
Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Andrew G. Bostom,Myra A. Carpenter,John W. Kusek,Andrew S. Levey,Lawrence G. Hunsicker,Marc A. Pfeffer,Jacob Selhub,Paul F. Jacques,Edward Cole,Lisa Gravens-Mueller,Andrew A. House,Clifton E. Kew,Joyce L. McKenney,Alvaro Pacheco-Silva,Todd E. Pesavento,John D. Pirsch,Stephen W. Smith,Scott D. Solomon,Matthew R. Weir +18 more
TL;DR: Treatment with a high-dose folic acid, B6, and B12 multivitamin in kidney transplant recipients did not reduce a composite cardiovascular disease outcome, all-cause mortality, or dialysis-dependent kidney failure despite significant reduction in homocysteine level.
Journal ArticleDOI
Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus : A Randomized, Multicenter, 24-Month Study
Hallvard Holdaas,Lionel Rostaing,Daniel Serón,Edward Cole,Jeremy R. Chapman,Bengt Fellström,Erik H. Strøm,Alan G. Jardine,Karsten Midtvedt,Uwe Machein,Bettina Ulbricht,Alexander Karpov,Philip J. O'Connell +12 more
TL;DR: Conversion to everolimus with CNI elimination or minimization a mean of 5.6 years after kidney transplantation had no overall renal benefit and was associated with more frequent adverse events and discontinuations.
Journal ArticleDOI
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial
Greg Knoll,Greg Knoll,Dean Fergusson,Dean Fergusson,Michaël Chassé,Paul C. Hébert,George A. Wells,Lee Anne Tibbles,Darin Treleaven,David C. Holland,Christine A. White,Norman Muirhead,Marcelo Cantarovich,Michel Paquet,Bryce A. Kiberd,Sita Gourishankar,Jean Shapiro,Ramesh Prasad,Edward Cole,Helen Pilmore,Valerie Cronin,Debora L. Hogan,Tim Ramsay,John S. Gill +23 more
TL;DR: Treatment with ramipril compared with placebo did not lead to a significant reduction in doubling of serum creatinine, end-stage renal disease, or death in kidney transplant recipients with proteinuria and the use of angiotensin-converting enzyme inhibitors is not supported.
Journal ArticleDOI
Incentives for organ donation: proposed standards for an internationally acceptable system.
Arthur J. Matas,Sally L. Satel,Stephen R. Munn,Janet Radcliffe Richards,Angeles Tan-Alora,Frederike Ambagtsheer,Micheal D. H. Asis,Leo Baloloy,Edward Cole,J Crippin,David C. Cronin,Abdallah S. Daar,James D. Eason,Richard N. Fine,Sander Florman,Richard B. Freeman,John J. Fung,Wulf Gaertner,Robert S. Gaston,Nasrollah Ghahramani,Ahad Ghods,Michelle Goodwin,Thomas Gutmann,Nadey S Hakim,Benjamin Hippen,Ajit Huilgol,Igal Kam,Arlene Lamban,Walter Land,Alan Norman Langnas,Reynaldo Lesaca,Gary A. Levy,RoseMarie Liquette,William H. Marks,Charles Miller,E. T. Ona,Glenda Eleanor P. Pamugas,Antonio Paraiso,Thomas Peters,David P. T. Price,Gurch Randhawa,Alan I. Reed,Keith Rigg,Dennis Serrano,Hans W. Sollinger,Sankaran Sundar,Lewis W. Teperman,Gert van Dijk,Willem Weimar,Romina Danguilan +49 more
TL;DR: It is believed that if systems based on guidelines for an acceptable system of incentives for donation were developed, harms would be no greater than those to today's conventional donors.